Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) EBIT Margin (2020 - 2023)

Historic EBIT Margin for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to 228.43%.

  • Candel Therapeutics' EBIT Margin rose 259038300.0% to 228.43% in Q4 2023 from the same period last year, while for Dec 2023 it was 1479.42%, marking a year-over-year increase of 265213800.0%. This contributed to the annual value of 1596.7% for FY2024, which is 1172800.0% down from last year.
  • Latest data reveals that Candel Therapeutics reported EBIT Margin of 228.43% as of Q4 2023, which was up 259038300.0% from 1324.51% recorded in Q3 2023.
  • In the past 5 years, Candel Therapeutics' EBIT Margin ranged from a high of 1581.77% in Q1 2023 and a low of 28987.1% during Q1 2022
  • Its 4-year average for EBIT Margin is 15193.5%, with a median of 17100.0% in 2021.
  • As far as peak fluctuations go, Candel Therapeutics' EBIT Margin plummeted by -170322600bps in 2021, and later soared by 305688700bps in 2023.
  • Over the past 4 years, Candel Therapeutics' EBIT Margin (Quarter) stood at 19758.06% in 2020, then fell by -26bps to 24967.74% in 2021, then dropped by -5bps to 26132.26% in 2022, then surged by 99bps to 228.43% in 2023.
  • Its EBIT Margin was 228.43% in Q4 2023, compared to 1324.51% in Q3 2023 and 1487.42% in Q2 2023.